Helix BioPharma Corp. (TSE:HBP – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday. The stock traded as low as C$0.94 and last traded at C$0.95, with a volume of 36861 shares changing hands. The stock had previously closed at C$1.14.
Helix BioPharma Stock Down 19.3%
The business’s 50 day moving average is C$1.62 and its 200 day moving average is C$1.65. The company has a market capitalization of C$70.27 million, a price-to-earnings ratio of -23.00 and a beta of 0.72. The company has a debt-to-equity ratio of 2.44, a quick ratio of 1.03 and a current ratio of 0.45.
Helix BioPharma Company Profile
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.
Further Reading
- Five stocks we like better than Helix BioPharma
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
- Tesla’s Semi Is Finally Here—But Will It Move the Stock?
- 5 Stocks Showing Why Pricing Power Matters More Than Government Money
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
